Current investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant results in managing excess mass and related 2 disease. Preclinical evidence suggest a novel process https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/